“In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, the global IVD Market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period.
Browse in-depth TOC on “In-Vitro Diagnostics Market”
347
– Tables
41 – Figures
426 – Pages
Download
PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703
The global IVD market is projected to reach USD 113.1
billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9%
during the forecast period. The growth of the In-Vitro Diagnostics/IVD Market
is mainly driven by the rising geriatric population and the subsequent growth
in the prevalence of chronic and infectious diseases, increasing adoption of
fully automated and POC instruments in developed regions, growing awareness
regarding diseases diagnosis in developing regions, and growing R&D
investments by industry players to launch new IVD products. Also, the
development of disease-specific markers and tests is expected to offer
potential growth opportunities to market players in the coming years. However,
the unfavorable reimbursement scenario is expected to restrain the growth of
this market during the forecast period.
In this report, the IVD market is segmented based on
product & service, technology, application, end user, and region.
“Reagents & kits segment accounted for the largest share in
the In-Vitro Diagnostics/IVD Market.”
Based on product and service, the In-Vitro Diagnostics Market is
segmented into reagents & kits, instruments, services, and data management
software. The reagents & kits segment accounted for the largest share of
68.1% of the market in 2020. Accessibility to a wide range of reagents and the
need for reliable, specific, and faster detection of chronic diseases and
genetic disorders in the early stages are expected to drive the growth of this
segment.
“Oncology segment is expected to witness the fastest growth in the
forecast period.”
Based on application, the In-Vitro Diagnostics Market is
segmented into infectious diseases, diabetes, Oncology, cardiology, drug
testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other
applications. In 2020, infectious diseases accounted for 34.1% of the IVD
market. The large share of this segment can be attributed to the rising
prevalence of infectious diseases and multi-drug-resistant infectious diseases
and the growing need for effective diagnostic tools for these diseases.
However, the oncology segment is projected to grow at the highest CAGR of 6.6%
during the forecast period. The increasing number of cancer cases across the
globe, the growing demand for personalized medicine, and the availability of
funding for cancer research are the major factors driving the market growth.
“Immunoassay/immunochemistry account for the largest share in the
IVD market.”
Based on technology, the In-Vitro Diagnostics Market is
segmented into immunoassay/immunochemistry, clinical chemistry, molecular
diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis
and other technologies. The immunoassay/immunochemistry segment accounted for
31% of the IVD technologies market in 2020. The growing preference for these
technologies in clinical diagnostics over conventional methods and the ability
of immunoassay/immunochemistry technologies to offer faster results with high
sensitivity and accuracy are contributing to the growth of this market segment.
“Hospital laboratories accounted for the largest share of IVD
market in 2020”
Based on the end user, the In-Vitro Diagnostics Market is
segmented into hospital laboratories, clinical laboratories, academic
institutes, POC (point-of-care) testing centers, patients, and other end users.
In 2020, hospital laboratories accounted for the largest share of 47% of the
market, followed by clinical laboratories (23.8%) and POC testing centers
(13%). Many diagnostic tests are carried out in hospitals. The acquisition of
smaller physician practices and groups by hospitals is becoming a noticeable
trend in the US healthcare industry; the continuation of this trend will support
the market for hospital laboratories.
Request
Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=703
“North
America accounted for the largest share of the IVD market in 2020”
The In-Vitro Diagnostics Market is divided into five major
regions— North America, Europe, Asia Pacific, Latin
America, and the Middle East & Africa. In 2020, North
America accounted for the largest share of 39.8% of the market, followed
by Europe (28%), Asia Pacific (22.9%), Latin
America (6.5%), and the Middle
East & Africa (2.9%). The In-Vitro Diagnostics/IVD Market
in North America is well established, with the US being the major
market in this region. Growth in the North American market is mainly driven by
the increasing per capita healthcare expenditure and technologically advanced
healthcare infrastructure in the region. Initiatives taken by different
government associations are also anticipated to boost market growth in the
coming years.
Key Market Players:
Roche Diagnostics (Switzerland), Siemens Healthineers (Germany),
Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are
the leading players in this market. Other players in this market are Johnson
& Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories
(US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho
Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).
About
MarketsandMarkets™
MarketsandMarkets™ provides
quantified B2B research on 30,000 high growth niche opportunities/threats which
will impact 70% to 80% of worldwide companies’ revenues. Currently servicing
7500 customers worldwide including 80% of global Fortune 1000 companies as
clients. Almost 75,000 top officers across eight industries worldwide approach
MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst
and SMEs at MarketsandMarkets™ are tracking global high growth markets
following the "Growth Engagement Model – GEM". The GEM aims at
proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "Knowledge
Store" connects over 200,000 markets and entire value chains for deeper
understanding of the unmet insights along with market sizing and forecasts of
niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441 Email:
sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ivd-in-vitro-diagnostics-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/ivd-in-vitro-diagnostics.asp
No comments:
Post a Comment